📖Complete GuideUpdated 2026🔬Evidence-Based

Survodutide Guide

The GLP-1/Glucagon Dual Agonist for

Complete guide to Survodutide (BI 456906) - Boehringer Ingelheim

MASH Resolution
83%
In Phase 2 trials, 83% of patients on the highest dose achieved MASH resolution without worsening fibrosis. This is the highest rate ever seen in a MA
Fibrosis Improvement
52%
52% of patients showed fibrosis improvement by at least one stage. Fibrosis (liver scarring) was previously considered largely irreversible—this sugge
Liver Fat Reduction
87%
Patients experienced up to 87% relative reduction in liver fat content. The glucagon component specifically drives fat out of the liver, addressing th
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
ACTIVE MEDICATIONS
SurvodutideB12
SURVODUTIDE
🔥 14
2
days away
Thursday · 7.5mg
Medication Supply
Survodutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
SurvodutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
ACTIVE MEDICATIONS
SurvodutideB12
SURVODUTIDE
🔥 14
2
days away
Thursday · 7.5mg
Medication Supply
Survodutide
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
SurvodutideRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

What Is Survodutide?

Survodutide (BI 456906) is a dual receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates both GLP-1 receptors (like Ozempic) and glucagon receptors—a unique combination that targets both appetite and metabolism.

Why glucagon? While glucagon is often associated with raising blood sugar, when combined with GLP-1, it dramatically increases energy expenditure and promotes fat burning—especially in the liver. This makes Survodutide particularly promising for fatty liver disease.

Administration: Once-weekly subcutaneous injection, similar to other GLP-1 medications.

02WHAT TO TRACK

The Dual Mechanism

01
🔬
GLP-1 Agonism
Reduces appetite and food intake. Slows gastric emptying. Improves insulin secretion. Lowers blood sugar. Proven weight loss mechanism
02
🔬
Glucagon Agonism
Increases energy expenditure. Promotes fat oxidation. Dramatically reduces liver fat. Improves lipid profiles. Enhances weight loss beyond GLP-1 alone
03
🔬
Survodutide vs Mounjaro
While both are dual agonists, they target different second receptors. Mounjaro = GLP-1 + GIP (enhances insulin). Survodutide = GLP-1 + Glucagon (burns fat, especially liver fat). This makes Survodutid
03KEY NUMBERS

Breakthrough MASH Results

📈
MASH Resolution
0%
In Phase 2 trials, 83% of patients on the highest dose achieved MASH resolution without worsening fibrosis. This is the highest rate ever seen in a MA
💪
Fibrosis Improvement
0%
52% of patients showed fibrosis improvement by at least one stage. Fibrosis (liver scarring) was previously considered largely irreversible—this sugge
🏆
Liver Fat Reduction
0%
Patients experienced up to 87% relative reduction in liver fat content. The glucagon component specifically drives fat out of the liver, addressing th
04KEY NUMBERS

Weight Loss Results

📈
Average Weight Loss
0.0%
At the highest dose (4.8mg weekly), participants lost an average of 18.7% of their body weight over 46 weeks—comparable to tirzepatide (Mounjaro).
💪
Many Participants
0%
05DOSING

Expected Dosing Schedule

Weeks 1-4
0.6mg weekly
Weeks 5-8
1.2mg weekly
Weeks 9-12
2.4mg weekly
Week 13+
4.8mg weekly
06WHAT TO TRACK

Side Effects

01
🔬
Common (GI-Related)
Nausea (most common). Vomiting. Diarrhea. Decreased appetite. Constipation
02
🔬
Glucagon-Related Considerations
Safety note: The GLP-1 component effectively prevents glucagon from raising blood sugar. In trials, Survodutide improved glycemic control despite the glucagon component.
07TIMELINE

Development Timeline

2023:
Phase 2 results published (obesity and MASH)
2024-2026:
Phase 3 trials ongoing for obesity and MASH
2026:
Expected Phase 3 completion
2027:
Potential FDA approval (obesity and/or MASH)
08WHAT TO TRACK

Who Will Benefit Most?

01
🔬
Ideal Candidates
Patients with fatty liver disease (MASH/NAFLD). Obesity with elevated liver enzymes. Those who haven't responded well to other GLP-1s. Patients wanting metabolic + liver benefits. Type 2 diabetics wit
02
🔬
The MASH Opportunity
MASH affects millions and can progress to cirrhosis and liver cancer. With no approved treatments, Survodutide could be the first FDA-approved medication for this condition.
09WHAT TO TRACK

Vital Protocol FAQs

01
🔬
Will Survodutide raise my blood sugar?
No. While glucagon alone raises blood sugar, the GLP-1 component in Survodutide effectively counteracts this. Clinical trials showed improved glycemic control, not worsened. The combination is designe
02
🎯
Is Survodutide only for people with liver disease?
No. Survodutide is being developed for both obesity AND MASH. You don't need liver disease to potentially benefit from its weight loss effects. However, if you do have fatty liver, Survodutide may off
03
🧬
How does Survodutide compare to Retatrutide for liver disease?
Both show excellent liver benefits due to their glucagon components. Survodutide's Phase 2 MASH data (83% resolution) is slightly ahead of Retatrutide's liver data, though direct comparisons are diffi
04
🔬
When will Survodutide be available?
Phase 3 trials are ongoing. If successful, FDA submission could occur in 2026, with potential approval in 2027. MASH indication may be approved before or alongside obesity indication.
10FAQ

Guide FAQs

Complete guide to Survodutide (BI 456906) - Boehringer Ingelheim

Yes. Shotlee supports tracking Survodutide doses, side effects, and health metrics. It is free to use.

PubMed, ClinicalTrials.gov, and the FDA website are the most reliable sources for current Survodutide research and regulatory updates. Peer-reviewed journals including the New England Journal of Medicine, The Lancet, and JAMA publish the most impactful clinical trial results. This guide is updated regularly to reflect the latest available evidence. Use Shotlee to track your personal protocol outcomes alongside the published research.

Before starting Survodutide, establish baseline measurements including body weight, waist circumference, blood pressure, and relevant lab work with your healthcare provider. Download Shotlee and begin logging your baseline metrics at least one week before starting treatment. This pre-treatment data provides the comparison point needed to objectively evaluate your treatment response over time. Additionally, discuss potential side effects and management strategies with your prescriber so you are prepared for the initial adaptation phase.

Evidence-based lifestyle modifications that complement Survodutide protocols include: maintaining adequate protein intake (1.2-1.6g per kg body weight per day) to preserve lean mass, performing resistance training two to three times per week, staying well hydrated with at least eight glasses of water daily, prioritizing seven to nine hours of quality sleep, managing stress through regular physical activity or mindfulness practices, and eating smaller more frequent meals during dose titration phases. Track these lifestyle factors alongside your Survodutide data in Shotlee to identify which combinations drive your best results.

Free · Always

Track Your Survodutide Protocol in Shotlee

Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.

📚References & sources

Start tracking